Skip to main content
. 2015 Dec 31;7(5):5769–5787. doi: 10.18632/oncotarget.6806

Figure 2. MALAT1 over-expression is associated with clinicopathological characteristics of HCC.

Figure 2

(A) The levels of MALAT1 in HCC tissues (n = 32) and in paired adjacent normal tissues (n = 32) were determined by qRT-PCR assays (means ± SD, n = 3) *P < 0.05 different from adjacent normal tissues. (B) The levels of MALAT1 were determined by qRT-PCR assays (means ± SD, n = 3) in tumors < 3 cm (n = 15) and in tumors ≥ 3 cm (n = 17). *P < 0.05, different from tumors < 3 cm. (C) The mRNA levels of MALAT1 (means ± SD, n = 3) in tumors of patients with clinical stage I–II (n = 10) and with clinical stage III–IV (n = 22) were measured by qRT-PCR assays. *P < 0.05, different from clinical stages I–II. Kaplan-Meier curves were constructed for survival of patients with HCC cancers divided according to the levels of MALAT1. (D) There were significantly (P = 0.005) shorter survival times for patients with high MALAT1 levels than for those with low MALAT1 levels. (E) The MALAT1 levels were determined by qRT-PCR (means ± SD, n = 3) for HCC cell lines (HepG2, SMMC-7721, Bel-7402, MHCC97H, and HCC-LM3) with different aggressive characteristics. L-02 cells were used as control cells.